In The Media

Bloomberg Business Week 2013-12-09 Judy Doetterl was a sales representative for Johnson & Johnson (JNJ) in 2004 when federal agents placed a hidden recording device on her and sent her to tape marketing presentations at

The Wall Street Journal 2013-11-19 The Wall Street Journal reports that Johnson & Johnson has agreed to pay at least $2.5 billion to settle nearly 8,000 hip implant lawsuits In its latest multibillion-dollar

The Chronicle of Higher Education 2013-11-08 Federal prosecutors on Thursday concluded another multibillion-dollar settlement with a major pharmaceutical company accused of illegally marketing its drugs. In this case, the company was Johnson &

Philadelphia Inquirer 2013-11-05 Sheller, P.C.’s representation of whistleblowers totals over $6 billion, with three of the top five pharmaceutical settlements in history: 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4

The Boston Globe 2013-08-22 Worcester’s UMass Memorial Medical Center has settled fraud charges with the attorney general in a whistleblower case alleging that it improperly sent bills for uninsured patients to a homeless

2014-12-19 The $2.2 Billion settlement with Johnson & Johnson Leads the Pack The Legal Intelligencer reported that the largest verdict and settlement award in Pennsylvania between August 2013 and August 2014 was handled
pharmalot,silverman,ed,risperdal,fda,petition

Lawyer Spars With FDA Over J&J Risperdal Court Documents by Ed Silverman, Pharmalot In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by

The Philadelphia Inquirer & “Fierce Pharma” 2013-07-10 The U.S. Food and Drug Administration is dragging its feet in addressing concerns that Johnson & Johnson’s antipsychotic drugs Risperdal and Invega are dangerous, a Philadelphia

The American Law Journal 2013-06-16 Attorney Stephen Sheller sparred with pharmaceutical defense attorney Hope Freiwald of Dechert law firm on the television program The American Law Journal. The attorneys, joined by Pharmalot author

2013-06-25 In a case involving a Philadelphia company, a divided U.S. Supreme Court ruled Monday that federal pharmaceutical laws preempt a person’s ability to sue in state court alleging that a generic drug